Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
- PMID: 17363731
- DOI: 10.1182/blood-2006-12-062125
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Abstract
To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid leukemia (AML). At MPD diagnosis, JAK2-V617F was detectable in 17 of 27 patients. Surprisingly, only 5 of 17 patients developed JAK2-V617F-positive AML, whereas 9 of 17 patients transformed to JAK2-V617F-negative AML. Microsatellite analysis in a female patient showed that mitotic recombination was not responsible for the transition from JAK2-V617F-positive MPD to JAK2-V617F-negative AML, and clonality determined by the MPP1 polymorphism demonstrated that the granulocytes and leukemic blasts inactivated the same parental X chromosome. In a second patient positive for JAK2-V617F at transformation, but with JAK2-V617F-negative leukemic blasts, we found del(11q) in all cells examined, suggesting a common clonal origin of MPD and AML. We conclude that JAK2-V617F-positive MPD frequently yields JAK2-V617F-negative AML, and transformation of a common JAK2-V617F-negative ancestor represents a possible mechanism.
Similar articles
-
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.Blood. 2006 Nov 15;108(10):3548-55. doi: 10.1182/blood-2005-12-013748. Epub 2006 Jul 27. Blood. 2006. PMID: 16873677
-
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.Br J Haematol. 2018 Jul;182(1):78-85. doi: 10.1111/bjh.15276. Epub 2018 May 16. Br J Haematol. 2018. PMID: 29767839
-
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.Blood. 2009 Feb 26;113(9):2022-7. doi: 10.1182/blood-2008-07-167056. Epub 2008 Dec 1. Blood. 2009. PMID: 19047681
-
The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. doi: 10.1055/s-2006-942754. Semin Thromb Hemost. 2006. PMID: 16810609 Review.
-
[Myeloproliferative diseases caused by JAK2 mutation].Rinsho Byori. 2009 Apr;57(4):357-64. Rinsho Byori. 2009. PMID: 19489438 Review. Japanese.
Cited by
-
JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?Am J Hematol. 2012 Nov;87(11):1028-36. doi: 10.1002/ajh.23243. Epub 2012 May 28. Am J Hematol. 2012. PMID: 22641564 Free PMC article. Review.
-
Single-cell analysis based dissection of clonality in myelofibrosis.Nat Commun. 2020 Jan 7;11(1):73. doi: 10.1038/s41467-019-13892-x. Nat Commun. 2020. PMID: 31911629 Free PMC article.
-
Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.Int J Mol Sci. 2019 Apr 13;20(8):1839. doi: 10.3390/ijms20081839. Int J Mol Sci. 2019. PMID: 31013941 Free PMC article. Review.
-
Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation.Leukemia. 2008 Jul;22(7):1472-4. doi: 10.1038/leu.2008.6. Epub 2008 Jan 31. Leukemia. 2008. PMID: 18239619 Free PMC article. No abstract available.
-
Acute myeloid leukemia with translocation (1;21).Mol Biol Rep. 2018 Jun;45(3):347-351. doi: 10.1007/s11033-018-4168-x. Epub 2018 Mar 22. Mol Biol Rep. 2018. PMID: 29569103 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous